AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Cancer therapeutic candidate licensed to Myriad Genetics.
2004 JAN 1 - (NewsRx.com & NewsRx.net) -- Maxim Pharmaceuticals (MAXM) announced the exclusive license of its MX90745 series of apoptosis-inducing compounds for the treatment of cancer to Myriad Genetics, Inc.
Compounds in the MX90745 series, specifically the current lead compound MX128495, have shown potency in the low nanomolar range in preclinical testing in multiple cancer types including prostate cancer, breast cancer, colorectal cancer, non-small cell lung cancer, small cell lung cancer, melanoma, and leukemia. The MX90745 series is one of more than 40 compound families identified by Maxim through its proprietary caspase-based, high-throughput screening system that targets the identification of compounds that modulate programmed cell death, or apoptosis.
"We are pleased to partner with Myriad on the development of MX128495, a compound that we believe has the potential to advance into human clinical trials in the near future," said Larry G. Stambaugh, Maxim's chairman and CEO. "We are impressed by Myriad's leadership in the development of its drug candidate R-flurbiprofen (MPC-7869) and the marketing of its predictive medicine tests."
"These novel and promising compounds are an excellent complement to Myriad's cancer therapeutic development programs," said ...
- Myriad Genetics, Inc. Names Jerry Lanchbury Senior Vice President of Research.
- Press release article from: PR Newswire January 22, 2003 700+ words
Myriad Genetics, Inc. has named Jerry Lanchbury...President and Chief Scientific Officer of Myriad Genetics, Inc. Dr. Lanchbury oversees all...research and development programs at Myriad Genetics, Inc. He joined Myriad from King...
- Myriad Genetics Awarded BRCA1 Composition of Matter Patent
- Press release article from: PR Newswire May 5, 1998 700+ words
...CITY, May 5 /PRNewswire/ -- Myriad Genetics, Inc. (Nasdaq: MYGN) was...is the fourth patent issued to Myriad Genetics for the BRCA1 gene. This most...Meldrum, President & CEO of Myriad Genetics, Inc. The BRCA1 gene was discovered...
- Myriad Genetics and Genetic Technologies Announce Strategic Licensing Agreement.
- Press release article from: PR Newswire October 28, 2002 700+ words
Myriad Genetics, Inc. and Genetic Technologies Limited...Under the terms of the agreement, Myriad Genetics will receive a broad, non-exclusive...its laboratory in the United States. Myriad Genetics has granted Genetic Technologies an...
- Myriad Genetics Awarded U.S. Patent On p16 Tumor Suppressor Gene; Frequency of...
- Press release article from: PR Newswire September 9, 1998 700+ words
...Sept. 9 /PRNewswire/ -- Myriad Genetics, Inc. (Nasdaq: MYGN) announced...of all tumors. Researchers at Myriad Genetics originally discovered that inherited...Meldrum, President and CEO of Myriad Genetics. "The p16 gene's involvement...
- Myriad Genetics Decodes Pufferfish Genome With International Consortium; Unique...
- Press release article from: PR Newswire October 25, 2001 700+ words
...Oct. 25 /PRNewswire/ -- Myriad Genetics, Inc. (Nasdaq: MYGN), used...programs to known human sequence. Myriad Genetics has full access to the Fugu data...of Research and Development at Myriad Genetics, Inc. "These tools will assist...
- Myriad Genetics Elects Robert Attiyeh to its Board of Directors; - Dale...
- Press release article from: PR Newswire December 4, 2003 700+ words
Myriad Genetics, Inc. announced today that it has...member of the Board of Directors of Myriad Genetics, Inc.," said Peter Meldrum, President...Stringfellow, Ph.D., a Director of Myriad Genetics since December 1991. As a Myriad Director...
- Myriad Genetics Names Richard Marsh As General Counsel.
- Press release article from: PR Newswire November 21, 2002 700+ words
Myriad Genetics, Inc. announced today that it has...Meldrum, President & CEO of Myriad Genetics, Inc. "We are pleased to welcome...leading biopharmaceutical company." Myriad Genetics, Inc. is a leading biopharmaceutical...
- Myriad Genetics is Exclusive Licensee of New Mayo Clinic Patent on Amyloid...
- Press release article from: PR Newswire June 29, 2005 700+ words
...PRNewswire-FirstCall/ -- Myriad Genetics, Inc. , announces the issuance...and Chief Executive Officer of Myriad Genetics, Inc. About Flurizan Flurizan...www.myriad.com/. Myriad Genetics, Inc. is a biopharmaceutical...
Source: HighBeam Research, Cancer therapeutic candidate licensed to Myriad Genetics.